In a mouse model of ovarian cancer, the use of glycomimetic peptides to target CD301/MGL was shown to activate dendritic cells (DCs) and immune cells that act against the tumor, leading to enhanced tumor protection, especially when these peptides were used in combination with immune checkpoint inhibitor (ICI) therapy [125, 126]. This evidence concerns the gene CLEC10A and neoplasm.